FDA Authorizes Novavax COVID Vaccine
The FDA issued an emergency use authorization for the Novavax COVID vaccine (adjuvanted) for Americans 18 years of age and older.
The FDA issued an emergency use authorization for the Novavax COVID vaccine (adjuvanted) for Americans 18 years of age and older.
A greater proportion of patients with severe, uncontrolled asthma had more significant clinical responses to tezepelumab (Tezspire) than placebo, according to research presented at ATS 2022.
The US FDA expanded the approval of remdesivir (Veklury, Gilead Sciences) to include pediatric patients 28 days of age and older weighing at least 3 kg with positive results of direct SARS-CoV-2 viral testing.
Moderna Inc has submitted a request to the US FDA to allow for a second booster (fourth dose) of its COVID-19 vaccine (mRNA-1273) in all US adults.
Read MoreThe US FDA approved the first Symbicort generic inhalation aerosol from Mylan Pharmaceuticals for the treatment of asthma and COPD.
Read MoreThe investigational long-acting monoclonal antibody Nirsevimab showed 74.5% efficacy against medically attended lower respiratory tract infections caused by RSV in healthy infants.
Read MoreFifty-seven percent of parents who are healthcare workers planned to vaccinate their children under age 5 as soon as a vaccine was approved.
Read MoreAn expanded ACTIV-6 study will test 600 mcg/kg of ivermectin daily for six days in patients who have had a positive COVID-19 test within the past 10 days, and have at least two symptoms of the illness for no more than seven days.
Read MoreThere is a slightly elevated risk of intracranial thrombosis events following vaccination with the AstraZeneca ChAdOx1-S COVID vaccine, according to two new studies published in Plos Medicine
Read MoreENA Respiratory and the COPD Foundation are partnering to develop an antiviral nasal spray to prevent and reduce incidence and severity of respiratory viral infections in people with chronic lung diseases like COPD.
Read MoreHealth Canada has approved GlaxoSmithKline and Medicago’s Covifenz COVID-19 vaccine, a plant-based virus-like particles, recombinant, adjuvanted vaccine, for adults age 18-64.
Read MoreBoehringer Ingelheim’s BI 1015550 is a PDE4B inhibitor with the potential to address both pulmonary fibrosis and inflammation associated with progressive fibrosing interstitial lung diseases.
Read MoreSanofi and GSK will submit data from both their booster and Phase 3 efficacy trials to the FDA and other international regulatory agencies for authorization of their Sanofi-GSK COVID-19 vaccine.
Read MoreResearchers say the hydrofluorocarbons in pressurized metered dose inhalers are potent greenhouse gases and switching to dry powder inhalers would cut emissions while not worsening asthma management.
Read MoreThe FDA has approved a generic version of roflumilast manufactured by Zydus Pharmaceuticals USA Inc for the treatment of COPD.
Read More